Skip to main content
Pharma Equity Group A/S logo

Pharma Equity Group A/S — Investor Relations & Filings

Ticker · BLVIS ISIN · DK0061155009 LEI · 2138008SUI4D917FKN20 CO Financial and insurance activities
Filings indexed 1,627 across all filing types
Latest filing 2014-11-28 AGM Information
Country DK Denmark
Listing CO BLVIS

About Pharma Equity Group A/S

https://bcbsfepvision.com/

Pharma Equity Group A/S is an investment company specializing in early-stage biotechnology, life science, and MedTech companies. The group's mission is to support its portfolio companies in developing novel therapies and effective medicines for unmet medical needs. A primary investment is its subsidiary, Reponex Pharmaceuticals, a clinical-stage biopharmaceutical company focused on developing treatments for serious, acute, and chronic inflammatory diseases. The company is actively expanding its portfolio through strategic acquisitions to support its growth.

Recent filings

Filing Released Lang Actions
AGM Information 2014
AGM Information Classification · 98% confidence The document is explicitly titled "Indkaldelse til ekstraordinær generalforsamling" (Notice of Extraordinary General Meeting) in Danish. It details the agenda, including a proposal for capital reduction, voting requirements, registration dates, and procedures for obtaining access cards, submitting written votes, and proxy forms. This content directly relates to the formal procedures and materials surrounding a shareholder meeting, specifically an Extraordinary General Meeting (EGM). While it mentions documents like the latest annual report, the primary purpose of this specific document is the notice and logistics for the meeting itself. This aligns best with the 'AGM Information' category (AGM-R), as EGMs follow similar procedural documentation standards as AGMs, focusing on shareholder assembly matters.
2014-11-28 English
Earnings Release 2014
Earnings Release Classification · 99% confidence The document explicitly states it is the 'Delårsrapportering 1. halvår 2014' (Interim Report for the first half of 2014) and provides detailed financial results (P&L, equity) for the period January 1 to June 30, 2014. This content aligns perfectly with the definition of a comprehensive financial report for a period shorter than a year. The document length (2545 chars) is substantial enough to be the report summary itself, not just an announcement of publication. Therefore, the classification is Interim / Quarterly Report (IR). H1 2014
2014-08-15 Danish
Interim / Quarterly Report 2014
Interim / Quarterly Report Classification · 95% confidence The document is a 'Delårsrapportering' (Interim Report) for the first half of 2014 for Blue Vision A/S. It contains substantive financial data, including profit/loss after tax, equity figures, and financial highlights for the period. Although it is short (2 pages), it provides the actual financial results rather than just announcing the availability of a separate report, thus qualifying as an Interim/Quarterly Report (IR). H1 2014
2014-08-15 English
Board/Management Information 2014
Board/Management Information Classification · 100% confidence The document is a short company announcement ('SELSKABSMEDDELELSE') dated July 11, 2014, titled 'Direktørskifte' (Change of Director). It explicitly states that the CEO, Morten Jensen, has resigned and names Staffan Mattson as the new CEO, detailing his background. This content directly matches the definition for Board/Management Information (MANG), which covers announcements of changes in senior management.
2014-07-11 Danish
Major Shareholding Notification 2014
Major Shareholding Notification Classification · 95% confidence The document is very short (277 characters) and explicitly states, 'Blue Vision A/S har i dag modtaget vedlagte meddelelse' (Blue Vision A/S has today received the attached announcement). The title mentions 'Storaktionærmeddelelse' (Major Shareholder Announcement). Since the text is merely an announcement that a document has been received/attached, and it concerns a major shareholder, it fits the criteria for a Report Publication Announcement (RPA) if it were announcing the publication of a report, or more specifically, a Major Shareholding Notification (MRQ) if the attached document is the actual notification. Given the context of 'Storaktionærmeddelelse' and the brevity suggesting it's just a cover note, MRQ is the most specific fit for the *subject matter* (Major Shareholding Notification), even though the *format* is an announcement. However, following the 'MENU VS MEAL' rule, if this is just a notification *about* a major shareholder filing, and not the filing itself, RPA or RNS might apply. Since 'Major Shareholding Notification' (MRQ) is a defined category, and this document explicitly references that subject matter, I will classify it as MRQ, assuming the attached document is the required filing, and this text is the accompanying cover letter/announcement of that filing being made public/received.
2014-06-11 Danish
Major Shareholding Notification 2014
Major Shareholding Notification Classification · 98% confidence The document is titled "Storaktionærmeddelelse vedrørende Blue Vision A/S" (Major Shareholder Announcement regarding Blue Vision A/S) and explicitly references Danish securities trading law (§ 29) and major shareholder regulations (§ 4, pkt. 8) for notification. It details the acquisition of voting power (proxy authority) over shares held by two entities (Neddi ApS and Ventum A/S), resulting in a total voting right of 21.50%. This content directly relates to changes in significant share ownership thresholds and voting rights held by major shareholders, which aligns precisely with the definition for Major Shareholding Notification (MRQ). It is not an AGM presentation, a full annual report, an earnings release, or a director's dealing report.
2014-06-11 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.